Melanoma Dispatch
2.7K views | +0 today
Follow
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Scooped by Cancer Commons
Scoop.it!

PD-1 Antibody Demonstrated Encouraging Activity in Metastatic Melanoma

PD-1 Antibody Demonstrated Encouraging Activity in Metastatic Melanoma | Melanoma Dispatch | Scoop.it

"Heavily pretreated patients with metastatic melanoma who received the humanized anti-PD-1 monoclonal antibody pidilizumab demonstrated encouraging rates of 12-month OS, according to results of a phase 2 study presented at the ASCO Annual Meeting.


“ 'Activity was previously seen [with pidilizumab] in two lymphoma populations in phase 2 studies,' researcher Michael B. Atkins, MD, deputy director of Georgetown-Lombardi Comprehensive Cancer Center in Washington, and professor of oncology and medicine at Georgetown University School of Medicine, said during a presentation. 'Correlative studies in those lymphoma populations supported a PD-1/PD-L1–linked mechanism of action, and importantly there was no change or an increase in PD-1–positive CD4 and CD8 lymphocytes and CD14 monocytes following the drug, excludingantibody-dependent cellular cytotoxicity of PD-1–positive cells as a consequence of therapy.' "


Editor's note: Pidilizumab is a new drug that that might benefit people with metastatic melanoma who have already been heavily treated. A recent clinical trial testing it in volunteer patients found some promising results, but further studies will be needed to see how to use pidilizumab most effectively, in terms of dosage and combining it with other drugs. Pidilizumab is an "anti-PD-1" immunotherapy, meaning that it interacts with a protein called PD-1 to boost a patient's own immune system to fight cancer. Learn more about immunotherapy treatments for melanoma at our Need to Know blog.

Cancer Commons's insight:

Healio  |  Jun 24, 2014

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

NICE Proposes Ipilimumab as a First Treatment for Advanced Skin Cancer

NICE Proposes Ipilimumab as a First Treatment for Advanced Skin Cancer | Melanoma Dispatch | Scoop.it

"People with advanced skin cancer should be able to receive ipilimumab as a first treatment, the National Institute for Health and Care Excellence (NICE) proposes.


"In final draft guidance, NICE recommends that the drug ipilimumab (also called Yervoy and manufactured by Bristol-Myers Squibb Pharmaceuticals Limited) is made available on the NHS as a first-line treatment for patients with advanced malignant melanoma which is either unresectable (when the full tumour cannot be removed) or metastatic (the cancer has spread to other parts of the body).


"Sir Andrew Dillon, NICE chief executive, said: 'We already recommend ipilimumab as a second-line treatment and so we are pleased to be able to propose extending that recommendation to first line treatment too.' "


Editor's note: The UK's public healthcare system is required to provide funding for treatments recommended by NICE. To learn more about targeted melanoma drugs like ipilimumab, read The Basics.

Cancer Commons's insight:

NICE  |  Jun 12, 2014

more...
No comment yet.